Dr. Shain Discusses Emerging Agents in Multiple Myeloma

Video

In Partnership With:

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.

Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Related Content
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
Andrew Kuykendall, MD

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023
Podcast
FDA

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024
Article
The FDA has approved idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

April 5th 2024
Article